Home Blog Page 1704

Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs

By
Advertorial Desk
-

BOSTON, Nov. 17, 2025 /PRNewswire/ — Bambusa Therapeutics, Inc. (“Bambusa”), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its oversubscribed Series A-2 financing, closed at a substantial valuation step-up over the prior round.

This Series A-2 financing reflects strong participation from Bambusa’s existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners L.P., Salvia GmbH, Janus Henderson Investors, Invus, ADAR1 Capital Management, and Dawn Biopharma (an investment platform controlled by KKR). Their continued commitment highlights growing confidence in Bambusa’s highly differentiated bispecific platform, rapid execution, and clinical momentum.

Proceeds will accelerate the development of BBT003 and BBT004, extending the company’s proven capability to move programs swiftly from concept to the clinic.

“In just 18 months, our team has advanced two bispecific programs, BBT001 and BBT002, from development candidate to clinical proof-of-concept, an unprecedented pace in I&I biologics, demonstrating what a small, highly coordinated team can achieve in a short period of time,” said Dr. Shanshan Xu, Founder and Chief Executive Officer of Bambusa Therapeutics. “This new financing enables us to apply that same momentum to BBT003 and BBT004. Closing the round at a significantly increased valuation is a clear reflection of the strength of our data, the speed and quality of our execution, and the deep conviction from our investors. 2026 will be a catalyst-rich year for Bambusa with more than 10 clinical readouts across multiple I&I indications.”

BBT001 and BBT002 — both built on Bambusa’s half-life-extended bispecific architecture — have progressed into Phase I studies in dermatology and respiratory indications, realizing the founding ambition to create transformative medicines that reshape the I&I landscape. BBT003 and BBT004 will be developed in gastroenterology and rheumatology, leveraging the same development engine that has driven Bambusa’s early clinical velocity.

Dr. Derek DiRocco, Partner at RA Capital Management, commented: “RA Capital Management is delighted to continue to support Bambusa as they progress their portfolio of potentially best-in-disease bispecific antibodies for various I&I indications deeper into the clinic. In the nine months since we led the Series A-1 financing, we have been thrilled with the rapid and flawless execution delivered by the Bambusa team. Over the next year we eagerly look forward to the extensive clinical data sets that will highlight the immense value across the Bambusa portfolio.”   

Key uses of proceeds:

  • Advance BBT003 and BBT004 through IND-enabling studies and into early clinical development, maintaining Bambusa’s pace of advancement.
  • Broaden Bambusa’s bispecific antibody platform into new I&I indications and deepen the pipeline.
  • Strengthen core development infrastructure to support rapid progression through upcoming clinical and regulatory milestones.

About Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company developing a portfolio designed to transform care across a wide spectrum of chronic diseases. Powered by an innovative antibody engineering platform featuring half-life extension and high-concentration subcutaneous delivery, Bambusa’s vision is to deliver transformative medicines for patients across every stage of life — setting a new pace for the next era of I&I therapeutics. For more information, visit www.bambusatx.com.

  • BBT001 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-31 with best-in-disease potential. It is currently in Phase I development for atopic dermatitis and other Type 2 inflammatory skin diseases.
  • BBT002 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-5 with best-in-disease potential. It is currently in Phase I development for Type 2 inflammatory disorders including COPD, asthma, CRSwNP, eosinophilic esophagitis, and food allergy.
  • BBT003 and BBT004 are preclinical programs focused on gastroenterology and rheumatology, respectively.

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

By
Advertorial Desk
-

SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.[1] POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.[2]

“Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.[3] “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds on Organon’s recent momentum of expanding our biosimilars portfolio in women’s health and oncology. Our collaboration with Henlius is critical to our goal of making health care more sustainable for US patients.”

“The FDA approval of POHERDY marks a significant milestone in Henlius’ global expansion and quality biologics development. As the first pertuzumab biosimilar approved in the US, this important achievement demonstrates our core capability to build a sustainable global R&D system grounded in rigorous scientific and regulatory standards. It also reflects Henlius’ steadfast commitment to its patient-centric philosophy and long-term global strategy,” said Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius. “We will continue accelerating the delivery of quality biologics to benefit more patients worldwide and create greater value for human health.”[2]

“The approval of POHERDY further underscores Henlius’ track record in international registration, together with our strength in quality management and commercialization collaboration,” said Ping Cao, Chief Business Development Officer and Senior Vice President of Henlius. “We look forward to working closely with our partner Organon to leverage our complementary strengths in supply chain, market, and distribution networks, jointly enhancing access to quality biologics and providing patients with treatment options that combine quality and affordability.”[2]

POHERDY is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. POHERDY is also indicated for use in combination with trastuzumab and chemotherapy as (i) neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer and (ii) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence. See full indications below.

Pertuzumab products can cause subclinical and clinical cardiac failure manifesting as decreased left ventricular ejection fraction (LVEF) and congestive heart failure (CHF). Evaluate cardiac function prior to and during treatment. Discontinue POHERDY treatment for a confirmed clinically significant decrease in left ventricular function. Exposure to pertuzumab products can cause embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception. See additional safety information below.

POHERDY was approved based on the review of a comprehensive data package, which includes analytical similarity, clinical pharmacokinetic studies, and comparative clinical studies demonstrating that POHERDY is highly similar to and interchangeable with the reference product PERJETA in terms of safety, purity, and potency (safety and effectiveness).[4],[5]

In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to multiple biosimilars, including POHERDY. The agreement covers exclusive global commercialization rights except for China.[6] The FDA approval of POHERDY will further enhance the partners’ oncology portfolio and their ability to deliver quality biologics to more patients.[2]

About POHERDY® (pertuzumab-dpzb)

POHERDY is a HER2/neu receptor antagonist indicated for:

  • Metastatic Breast Cancer (MBC): POHERDY is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
  • Early Breast Cancer (EBC): POHERDY is indicated for use in combination with trastuzumab and chemotherapy for:
    • The neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
    • The adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence

SELECTED SAFETY INFORMATION

LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY

  • Pertuzumab products can cause subclinical and clinical cardiac failure manifesting as decreased left ventricular ejection fraction (LVEF) and congestive heart failure (CHF). Evaluate cardiac function prior to and during treatment. Discontinue POHERDY treatment for a confirmed clinically significant decrease in left ventricular function.
  • Exposure to pertuzumab products can cause embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.

CONTRAINDICATIONS

POHERDY is contraindicated in patients with known hypersensitivity to pertuzumab products or to any of its excipients.

WARNINGS AND PRECAUTIONS

Left Ventricular Dysfunction Pertuzumab products can cause left ventricular dysfunction, including symptomatic heart failure. Decreases in LVEF have been reported with drugs that block HER2 activity, including pertuzumab products.

Assess LVEF prior to initiation of POHERDY and at regular intervals during treatment to ensure that LVEF is within normal limits. If the LVEF declines and has not improved, or has declined further at the subsequent assessment, consider permanent discontinuation of POHERDY and trastuzumab.

In the pertuzumab-treated patients with MBC in CLEOPATRA, left ventricular dysfunction occurred in 4% of patients, and symptomatic left ventricular systolic dysfunction (LVSD) (congestive heart failure) occurred in 1% of patients. Patients who received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF or left ventricular dysfunction.

In patients receiving pertuzumab as a neoadjuvant treatment in combination with trastuzumab and docetaxel in NeoSphere, LVEF decline >10% and a drop to <50% occurred in 8% of patients, and left ventricular dysfunction occurred in 3% of patients. LVEF recovered to ≥50% in all of these patients.

In patients receiving neoadjuvant pertuzumab in TRYPHAENA, LVEF decline >10% and a drop to <50% occurred in 7% of patients treated with pertuzumab plus trastuzumab and fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by pertuzumab plus trastuzumab and docetaxel, 16% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC, and 11% of patients treated with pertuzumab in combination with docetaxel, carboplatin, and trastuzumab (TCH). Left ventricular dysfunction occurred in 6% of patients treated with pertuzumab plus trastuzumab and FEC followed by pertuzumab plus trastuzumab and docetaxel, 4% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC, and 3% of patients treated with pertuzumab in combination with TCH. Symptomatic LVSD occurred in 4% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC, 1% of patients treated with pertuzumab in combination with TCH, and none of the patients treated with pertuzumab plus trastuzumab and FEC followed by pertuzumab plus trastuzumab and docetaxel. LVEF recovered to ≥50% in all but 1 patient.

In patients receiving neoadjuvant pertuzumab in BERENICE, in the neoadjuvant period, LVEF decline ≥10% and a drop to <50% as measured by ECHO/MUGA assessment occurred in 7% of patients treated with pertuzumab plus trastuzumab and paclitaxel following dose-dense doxorubicin and cyclophosphamide (ddAC) and 2% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC. Ejection fraction decreased (asymptomatic LVD) occurred in 7% of patients treated with pertuzumab plus trastuzumab and paclitaxel following ddAC and 4% of the patients treated with pertuzumab plus trastuzumab and docetaxel following FEC in the neoadjuvant period. Symptomatic LVSD (New York Heart Association [NYHA] Class III/IV Congestive Heart Failure) occurred in 2% of patients treated with pertuzumab plus trastuzumab and paclitaxel following ddAC and none of the patients treated with pertuzumab plus trastuzumab and docetaxel following FEC in the neoadjuvant period.

In patients receiving adjuvant pertuzumab in APHINITY, the incidence of symptomatic heart failure (NYHA Class III/IV) with a LVEF decline ≥10% and a drop to <50% was 0.6%. Of the patients who experienced symptomatic heart failure, 47% of pertuzumab-treated patients had recovered (defined as 2 consecutive LVEF measurements above 50%) at the data cutoff. The majority of the events (86%) were reported in anthracycline-treated patients. Asymptomatic or mildly symptomatic (NYHA Class II) declines in LVEF ≥10% and a drop to <50% were reported in 3% of pertuzumab-treated patients, of whom 80% recovered at the data cutoff.

Pertuzumab products have not been studied in patients with a pretreatment LVEF value of <50%; a prior history of CHF; decreases in LVEF to <50% during prior trastuzumab therapy; or conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment, or a cumulative prior anthracycline exposure to >360 mg/m2 of doxorubicin or its equivalent.

Embryo-Fetal Toxicity

Based on its mechanism of action and findings in animal studies, pertuzumab products can cause fetal harm when administered to a pregnant woman. Pertuzumab products are HER2/neu receptor antagonists. Cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported with use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy.

Verify the pregnancy status of females of reproductive potential prior to the initiation of POHERDY. Advise pregnant women and females of reproductive potential that exposure to POHERDY in combination with trastuzumab during pregnancy or within 7 months prior to conception can result in fetal harm, including embryo-fetal death or birth defects. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of POHERDY in combination with trastuzumab.

Infusion-Related Reactions

Pertuzumab products can cause serious infusion reactions, including fatal events.

In CLEOPATRA, on the first day, when only pertuzumab was administered, infusion-related reactions occurred in 13% of patients, and <1% were Grade 3 or 4. The most common infusion reactions (≥1%) were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity, and vomiting. During the second cycle when all drugs were administered on the same day, the most common infusion reactions in the pertuzumab-treated group (≥1%) were fatigue, dysgeusia, hypersensitivity, myalgia, and vomiting.

In APHINITY, when pertuzumab was administered in combination with trastuzumab and chemotherapy on the same day, infusion-related reactions occurred in 21% of patients, with <1% of patients experiencing Grade 3-4 events.

Observe patients closely for 60 minutes after the first infusion and for 30 minutes after subsequent infusions of POHERDY. If a significant infusion-related reaction occurs, slow or interrupt the infusion, and administer appropriate medical therapies. Monitor patients carefully until complete resolution of signs and symptoms. Consider permanent discontinuation in patients with severe infusion reactions.

Hypersensitivity Reactions/Anaphylaxis

Pertuzumab products can cause hypersensitivity reactions, including anaphylaxis.

In CLEOPATRA, the overall frequency of hypersensitivity/anaphylaxis reactions was 11% in pertuzumab-treated patients, with Grade 3-4 hypersensitivity reactions and anaphylaxis occurring in 2% of patients.

In NeoSphere, TRYPHAENA, BERENICE, and APHINITY, hypersensitivity/anaphylaxis events were consistent with those observed in CLEOPATRA. In APHINITY, the overall frequency of hypersensitivity/anaphylaxis was 5% in the pertuzumab-treated group. The incidence was highest in the pertuzumab plus TCH–treated group (8%), with 1% Grade 3-4 events.

Observe patients closely for hypersensitivity reactions. Severe hypersensitivity, including anaphylaxis and fatal events, has been observed in patients treated with pertuzumab products. Angioedema has been described in postmarketing reports. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use prior to administration of POHERDY.  

ADVERSE REACTIONS

Metastatic Breast Cancer 
The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.

Neoadjuvant Treatment of Breast Cancer
The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia.

The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of FEC were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia.

The most common adverse reactions (>30%) with pertuzumab in combination with TCH were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia.

The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddAC were nausea, diarrhea, alopecia, fatigue, constipation, peripheral neuropathy, and headache.

The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of FEC were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia.

Adjuvant Treatment of Breast Cancer 
The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy, and vomiting.

Before prescribing POHERDY, please read the Prescribing Information, including the Boxed Warning about left ventricular dysfunction and embryo-fetal toxicity. 

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 10 products have been approved for marketing across multiple countries and regions, and 3 marketing applications have been accepted for review in China and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company’s launched products include HANSIZHUANG (serplulimab, trade name: Hetronifly in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANLIKANG (rituximab), the first China-developed biosimilar, denosumab BILDYOS and BILPREVDA, and pertuzumab POHERDY. What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.

To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.

About Organon

Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about expanding access to treatments for patients with HER2-positive breast cancer, the potential market opportunity for POHERDY, the expansion of Organon’s biosimilars portfolio, Organon’s collaboration with Henlius, and Henlius’ global expansion and biologics development. Forward-looking statements may be identified by words such as “goal,” “continue,” “forward,” “vision,” “mission,” “expect,” “explore,”  “future,” “believes,” “will,” “potential,” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, an inability to market HLX11, an investigational biosimilar of PERJETA (pertuzumab), in Europe; expanded brand and class competition in the markets in which Organon operates; trade protection measures and import or export licensing requirements, including the direct and indirect impacts of tariffs (including any potential pharmaceutical sector tariffs), trade sanctions or similar restrictions by the US or other governments; changes in US and foreign federal, state and local governmental funding allocations including the timing and amounts allocated to Organon’s customers and business partners; economic factors over which Organon has no control, including changes in inflation, interest rates, recessionary pressures, and foreign currency exchange rates; difficulties with performance of third parties Organon relies on for its business growth; the failure of any supplier to provide substances, materials, or services as agreed, or otherwise meet their obligations to us; the increased cost of supply, manufacturing, packaging, and operations; difficulties developing and sustaining relationships with commercial counterparties; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to or affecting Medicare, Medicaid and health care reform, pharmaceutical pricing and reimbursement, access to our products, international reference pricing, including Most-Favored-Nation drug pricing, and other pricing-related initiatives and policy efforts; an inability to fully execute on Organon’s product development and commercialization plans; manufacturing difficulties or delays; disruptions at the US Food and Drug Administration, the US Securities and Exchange Commission (the “SEC”) and other US and comparable foreign government agencies; changes in government laws and regulations in the United States and other jurisdictions, including laws and regulations governing the research, development, approval, clearance, manufacturing, supply, distribution, and/or marketing of our products and related intellectual property, environmental regulations, and the enforcement thereof affecting Organon’s business; efficacy, safety or other quality concerns with respect to our marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, labeling changes, or declining sales; future actions of third parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing health care insurance coverage; the failure by Organon or its third party collaborators and/or their suppliers to fulfill our or their regulatory or quality obligations; and volatility of commodity prices, fuel, shipping rates that impact the costs and/or ability to supply Organon’s products. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K (as amended), Quarterly Reports on Form 10-Q (as amended), Current Reports on Form 8-K, and other SEC filings, available at the SEC’s Internet site (www.sec.gov).

PERJETA is a trademark registered in the US by Genentech, Inc.; Organon is not associated with this trademark owner.

[1].     PERJETA. Prescribing Information. Genentech, Inc.; 2025.

[2].     Overview for health care professionals. US Food and Drug Administration. Updated August 1, 2024. Accessed March 13, 2025. https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals 

[3].     Key statistics for breast cancer. American Cancer Society. Updated May 5, 2025. Accessed November 14, 2025. https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html 

[4].     Review and approval. US Food and Drug Administration. December 13, 2022. Accessed July 28, 2025. https://www.fda.gov/drugs/biosimilars/review-and-approval 

[5].     Biosimilar product regulatory review and approval. US Food and Drug Administration. Accessed May 1, 2025. https://www.fda.gov/files/drugs/published/Biosimilar-Product-Regulatory-Review-and-Approval.pdf 

[6].     Organon enters into global license agreement to commercialize Henlius’ investigational Perjeta® (pertuzumab) and Prolia®/Xgeva® (denosumab) biosimilar candidates. Organon. June 13, 2022. Accessed July 28, 2025. https://www.organon.com/news/organon-enters-into-global-license-agreement-to-commercialize-henlius-investigational-perjeta-pertuzumab-and-prolia-xgeva-denosumab-biosimilar-candidates/ 

© 2025 Organon group of companies. All rights reserved. US-PER-110000   11/25

 

Galaxy Macau Presents a Standout OFF MENU Festival during Macau Grand Prix Weekend, Cementing the Luxury Resort as Asia’s Home of Gastronomy and Entertainment

By
Advertorial Desk
-

13 international master chefs and mixologists brought culinary perfection to sold-out sessions at the Galaxy Macau Cabanas, vibrantly bringing the themes of Ocean, Sky and Land to life against a glittering al fresco backdrop of live music and DJ sounds.


MACAU SAR – Media OutReach Newswire – 17 November 2025 – Signalling the third year in its standout gastronomic event series, Galaxy Macau Presents Tatler Off Menu concluded this year’s edition on November 14 and 15 at Galaxy Macau, drawing over 1,000 discerning foodies over three energy-packed sessions. Creative culinary artistry and masterful mixology shone through, against a backdrop of energetic live performances and elevated vibes at the Cabanas – Galaxy’s ultra-sophisticated al fresco, poolside location.

Eleven of the biggest names in the culinary world and two mixology greats joined hands to present an event of gastronomic wonder at the Galaxy Macau Cabanas, curating a multitude of epicurean highlights, wrapping up the 3rd Galaxy Macau Presents Tatler Off Menu.
Eleven of the biggest names in the culinary world and two mixology greats joined hands to present an event of gastronomic wonder at the Galaxy Macau Cabanas, curating a multitude of epicurean highlights, wrapping up the 3rd Galaxy Macau Presents Tatler Off Menu.

This year’s epicurean spectacle celebrated the essences of Ocean, Sky and Land; pampering guests with a feast of innovative servings that broadened the horizons of gastronomic indulgence. Amidst the breezy autumn sun and transitioning into the vibe-filled night surrounded by the glittering panorama of Galaxy Macau, guests savoured creations from 11 culinary masters – some debuting for the first time in Macau – who have collectively garnered a total of 13 Michelin stars among other awards from Asia’s and the World’s 50 Best Restaurants and Bars, as well as Black Pearl recognition.

Galaxy Macau Presents Tatler Off Menu concluded its iconic third edition on November 14 and 15, with a resounding turnout of over 1,000 guests. Discerning gourmands and foodies gathered to celebrate the leading edge of culinary artistry and innovation, highlighting Macau’s status as a UNESCO Creative City of Gastronomy.
Galaxy Macau Presents Tatler Off Menu concluded its iconic third edition on November 14 and 15, with a resounding turnout of over 1,000 guests. Discerning gourmands and foodies gathered to celebrate the leading edge of culinary artistry and innovation, highlighting Macau’s status as a UNESCO Creative City of Gastronomy.

Chef Masaaki Miyakawa, founder of the Three-Michelin-starred Sushi Miyakawa in Hokkaido and the eponymous One-Michelin-starred Sushi Kissho by Miyakawa at Galaxy Macau, crafted his signature Black Abalone with Liver Sauce – a perfect pairing. Chef Jingye Xu from Two-Michelin-starred 102 House in Shanghai, revolved around umami with Steamed Cod with Prawn Sauce and Clam Juice. A prodigious talent since the age of 14, Jakarta-born-and-raised Chef Aditya Muskita – a Tatler Best Indonesia winner – infused Southeast Asian spices such as Ginger Flower in his aromatic and flavourful creation: Hokkaido Scallops, Smoked Ginger Flower Curry, Calamansi. This wrapped up the trio of delicacies making up the Ocean category.

Guests savoured a symphony of gourmet delights and creative mixology, experiencing an unforgettable sensory journey in the breezy al fresco surrounds of Galaxy Macau.
Guests savoured a symphony of gourmet delights and creative mixology, experiencing an unforgettable sensory journey in the breezy al fresco surrounds of Galaxy Macau.

For the Sky theme, Executive Chef Chek Keong Chan of Two-Michelin-starred Feng Wei Ju at StarWorld Hotel played magic with bamboo fungus, matsutake, egg white, squab and tofu in a double-boiled bouillon, presented in a Chinese ceramic pot. Chef Min-Chul Kang from One-Michelin-starred KANG MINCHUL Restaurant in Seoul celebrated his Korean root by crafting “Chogyetang” – a cold chicken soup – to create a contrast between succulence, sour and spiciness. Chef Varun Totlani from Masque in Mumbai, ranked #19 in the Asia’s 50 Best Restaurants, revealed a superior Duck Confit and added Gassi and Vattayappam for an Indian twist.

Galaxy Macau, Asia’s leading luxury resort, promises a world of gastronomic options and culinary creativity throughout over 120 dining concepts, providing a benchmark for industry excellence in Macau, a UNESCO Creative City of Gastronomy.
Galaxy Macau, Asia’s leading luxury resort, promises a world of gastronomic options and culinary creativity throughout over 120 dining concepts, providing a benchmark for industry excellence in Macau, a UNESCO Creative City of Gastronomy.

The Land theme saw Chef Hiroyasu Kawate from the coveted Two-Michelin-starred eatery Florilège in Tokyo elevating the freshness of Japanese Daikon – white radish – by gently simmering the vegetable in a broth made with kombu, bonito flakes and miso, encapsulating every drop of umami. Hong Kong’s culinary son – founder of One-Michelin-starred VEA Hong Kong, Chef Vicky Cheng, decided to celebrate Cantonese gastronomy with the aromatic and decadent Lo Sui Fresh Pork Soup with Flat Rice Noodles. Originated in Teochew (Chaozhou) in eastern Guangdong Province, “Lo Sui” or “master stock” is best known for its consistency using a multitude of aromatic spices. Chef Cheng braised same-day-slaughtered pork in the stock to capture the robust and complex fragrance to present to diners at the event. Chef Marino D’Antonio of One-Michelin-starred 8½ Otto e Mezzo BOMBANA at Galaxy Macau presented slow-braised ox tongue, finished with pumpkin puree and roasted mushroom – a comfort dish filled with tender textures.

Asia’s Best Pastry Chef in World’s 50 Best Awards, Chef Fabrizio Fiorani of Zucchero X Fabrizio Fiorani in Rome, presented his “Signature FF Tiramisu”, comprising crucial elements of the most popular Italian dessert plated to foster a visual surprise, while retaining the layered flavours of Tiramisu. Simultaneously, Galaxy Macau’s very own Executive Pastry Chef Lok Hin Yam, awarded “Best Pastry Chef” by Tatler Best Hong Kong & Macau 2025, built upon the renowned cocktail Old Fashioned to create “Chocolate Hin’s Fashion”. A layered stack of smoked 80% chocolate mousse, mandarin compote and whisky passion fruit cream, the dessert was presented in a cocktail glass, but not before Chef Hin had sprinkled flaming cinnamon powder to enliven the sensory experience.

Head Mixologist Billy Choi from Pony & Plume – the cocktail and whisky bar and divan at Capella at Galaxy Macau – crafted the “Plummy Symphony” cocktail and the “Sapphire Bliss” mocktail to wrap up diners’ wondrous journey. Master Mixologist Ajit Gurung, helming the bar of Asia’s 50 Best Bars’ #32, The Savory Project in Hong Kong, played with flavour with “Strawberry Salsa”, a refreshingly complex mocktail, and “The Beef Salad”, a cocktail served with a piece of beef jerky that exploded with the aromas of Thai Beef Salad on the palate.

Trending DJs Cocoa Zhou and Hansel delivered captivating music sets throughout the three sessions, elevating the vibes to exhilarating heights amid rhythmic beats. The Raffles Trio appeared on a floating stage, playing contemporary classics with a twist, together with vocalists Amanda and Elisa.

Creating a stage for the finest talents in contemporary gastronomy, Galaxy Macau Presents Tatler Off Menu promises culinary creativity to the max throughout over 120 dining concepts at the award-winning luxury resort, in addition to cementing Macau’s status as a “UNESCO Creative City of Gastronomy”.

For more information about Galaxy Macau, please visit www.galaxymacau.com.

Hashtag: #GalaxyMacau

The issuer is solely responsible for the content of this announcement.

ABOUT GALAXY MACAU INTEGRATED RESORT

Galaxy Macau™, The World-class Luxury Integrated Resort delivers the “Most Spectacular Entertainment and Leisure Destination in the World”. Developed at an investment of HK$43 billion, the property covers 1.1 million-square-meter of unique entertainment and leisure attractions that are unlike anything else in Macau. Nine award-winning world-class luxury hotels provide close to 5,000 rooms, suites and villas. They include Banyan Tree Macau, Galaxy Hotel™, Hotel Okura Macau, JW Marriott Hotel Macau, The Ritz-Carlton, Macau, Broadway Hotel, Raffles at Galaxy Macau, Andaz Macau, and the opening-soon Capella at Galaxy Macau. Unique to Galaxy Macau, the 75,000-square-meter Grand Resort Deck features the world’s longest Skytop Adventure Rapids at 575-meters, the largest Skytop Wave Pool with waves up to 1.5-meters high and 150-meters pristine white sand beach. Two five-star spas from Banyan Tree Spa Macau and The Ritz- Carlton Spa, Macau help guests relax and rejuvenate.

As the dining destination in Asia, Galaxy Macau offers a wide variety of gastronomic delights, exquisite experiences and ingredients of the finest quality with over 120 dining options from Michelin dining to authentic delicacies.

Embark on a delightful and rewarding journey at Galaxy Promenade, the one-stop shopping destination boasting some of the world’s most iconic luxury brands. Be the first to get the latest limited-edition items; explore fascinating pop-ups by coveted labels and revel in fabulous shopping rewards and privileges. Our VIPs are entitled to a highly-curated experience with dedicated personal shoppers at guests’ service, and be invited to exclusive luxury brand events. A different calibre of privileges and rewards also await. Discover the joys of fashion and stand at the forefront of style and sophistication—Galaxy Promenade has everything guests need to stay ahead of the style game.

Galaxy Cinemas takes immersive movie experiences to the next level with the latest audio-visual technology, ultra-luxurious facilities and bespoke services; CHINA ROUGE, one-of-a-kind cabaret lounge that evokes the glamor of Shanghai’s golden era with stylish entertainment and customizable surrounds; and Foot Hub, which presents the traditional art of reflexology for authentic relaxation and revitalization. For Authentic Macau Flavours and Vibrant Asian Experiences, Broadway Macau – just a 90-second walk via a bridge from Galaxy Macau, has over 35 Authentic Macau & Asian Flavours at Broadway Food Street. The 2,500-seat Broadway Theatre plays host to world-class entertainers and a diverse array of cultural events.

Meeting, incentive and banquet groups are also catered to with a portfolio of unique venues in Galaxy Macau and an expert service team. Galaxy International Convention Center (GICC) is the latest addition to the Group’s ever-expanding integrated resort precinct and will usher in a new era for the MICE industry in Macau. GICC is a world-class event venue featuring 40,000-square-meters of total flexible MICE, and the 16,000-seat Galaxy Arena – the largest indoor arena in Macau.

For more details, please visit , and .

Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

By
Advertorial Desk
-

DURHAM, N.C. and SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ — Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.

Lunit and Labcorp collaborate to advance the real-world use of AI in oncology through digital pathology research
Lunit and Labcorp collaborate to advance the real-world use of AI in oncology through digital pathology research

The collaboration aims to leverage Labcorp’s extensive clinical and pathology expertise alongside Lunit’s cutting-edge AI algorithms to transform how tumor microenvironments are analyzed and interpreted. By combining high-resolution whole-slide imaging with AI-powered spatial profiling, the collaboration seeks to generate new insights that can enhance biomarker discovery and guide precision immuno-oncology strategies.

First Collaborative Studies Presented at SITC and AMP

The first outcome of the collaboration was showcased at two leading scientific conferences:

  • Society for Immunotherapy of Cancer (SITC): Study demonstrated how AI-based spatial profiling and machine learning can identify immune-active subtypes of non-small cell lung cancer (NSCLC) tumors with the MET exon 14 skipping mutation, which are associated with improved immunotherapy outcomes. Using Lunit SCOPE IO®, researchers analyzed more than 370 pathology slides to characterize immune phenotypes across different types of MET alterations, including exon 14 skipping, amplification, or no mutation (wildtype). Immune gene expression analysis further validated the AI-defined immune phenotypes and revealed key immune response pathways driving the inflamed phenotype, underscoring the predictive power of AI-based spatial profiling in MET-mutated NSCLC.
  • Association for Molecular Pathology (AMP): Study highlighted distinct tumor-immune microenvironments linked to different MET alterations in NSCLC, revealing immune-desert phenotypes in MET-amplified tumors, and inflamed phenotypes in those with MET exon 14 skipping tumors.

“Collaborating with Labcorp, one of the most respected leaders in diagnostics and clinical research, marks an important step toward expanding the real-world use of AI in oncology. These early studies show how AI can reveal meaningful, predictive biomarkers hidden within pathology slides,” said Brandon Suh, CEO of Lunit. “It’s a clear example of how digital pathology and AI can work hand in hand to advance precision oncology understanding, bridging discovery research and real-world clinical care.”

“Our collaboration with Lunit aims to turn complex pathology data into meaningful insights,” said Shakti Ramkissoon, M.D., Ph.D., MBA, vice president and medical lead for oncology at Labcorp. “These studies demonstrate how AI-powered digital pathology can reveal patterns within tumors—ultimately helping to guide treatment decisions, inform biomarker development, and pave the way for more personalized cancer care.”

Labcorp and Lunit plan to further broaden their collaboration by applying digital pathology AI to additional cancer types and genomic correlations.

###

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Following the integration of Volpara, Lunit now offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while Lunit SCOPE platform is used in research partnership with global pharma leaders for biomarker development and companion diagnostics.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io/en.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to the collaboration between Lunit and Labcorp and the potential benefits, uses and applications of artificial intelligence-powered digital pathology. Actual results could differ materially from those suggested by forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Supercent Wins “AI Innovation Pioneer” Award at Think Apps @ The Google Apps Summit

By
Advertorial Desk
-

SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ — Supercent, led by CEO Junsik Kong, has won the “AI Innovation Pioneer” award at Think Apps @ The Google Apps Summit, held on November 12 in Ho Chi Minh City, Vietnam.

From left Jihoon Byun, Executive Director for New Business at Supercent, and Scott Sheffer, Vice President at Google, at the Think Apps @ Google Apps Summit Hall of Fame ceremony
From left Jihoon Byun, Executive Director for New Business at Supercent, and Scott Sheffer, Vice President at Google, at the Think Apps @ Google Apps Summit Hall of Fame ceremony

The Google APAC Apps Summit is an annual flagship conference hosted by Google for app and game publishers and developers across the Asia-Pacific region. This year marked the first integration of two previously separate events — “APAC App Summit” and “Think Apps Vietnam” — into a unified conference format under the name Think Apps @ The Google Apps Summit. The Ho Chi Minh City event brought together industry leaders, technical experts, and developers from across APAC to share cutting-edge business achievements and innovation stories, while fostering meaningful networking opportunities.

As part of the program, the summit hosts an annual “Hall of Fame” session — an initiative dedicated to honoring esteemed app developers and publishers who have demonstrated exceptional impact and made significant contributions to the industry. This year’s Hall of Fame recognized winners across four categories:

  • Growth & Diversification Master
  • User Experience & Engagement Wizard
  • AI Innovation Pioneer
  • Social & Community Impact Powerhouse

Among these, Supercent was honored with the “AI Innovation Pioneer” title, underscoring its leadership in applying AI at scale across the publishing value chain.

Recognition for AI-Driven Publishing Excellence
The “AI Innovation Pioneer” award recognizes app developers who are at the forefront of leveraging Artificial Intelligence (AI), Machine Learning (ML), or Generative AI to create groundbreaking features and enhance user experiences. It celebrates businesses that are pushing the boundaries of intelligent technology, demonstrated by novel AI applications — such as hyper-personalization and advanced predictive analytics — and measurable AI impact, including quantifiable improvements in engagement and conversion metrics.

Supercent stood out for embracing AI not merely as a productivity tool, but as a fundamental operating philosophy. The company has transformed its traditional, human-centered Publishing System Loop (PSL) into an “AI-Driven Publishing Framework”, where AI plays an integral role across development, quality assurance, and live operations.

Centering its efforts around a dedicated Chief AI Officer (CAIO) organization, Supercent has implemented company-wide AI education and experimentation. The number of employees actively using AI in their day-to-day work has expanded from fewer than 20 in 2024 to virtually the entire workforce in 2025. Across development, creative, and marketing, the company has introduced systems such as “Night Coder” (an AI code review system), AI-powered QA, generative art workflows, and ROAS prediction models, significantly boosting automation and the precision of forecasting.

CEO Junsik Kong commented:
“This award is recognition on the global stage of Supercent’s ‘contents-tech’ vision and our AI-driven operating model. In today’s fast-changing mobile game market, AI is no longer optional — it’s the default assumption.”

He continued:
“At Supercent, AI is the core engine that connects content and technology. It allows us to simultaneously accelerate our publishing speed and raise product quality. We will continue to push AI-based innovation as a contents-tech company and build a publishing model that works not only across APAC but in global markets as well.”

CAIO(Chief AI Officer) Donggeon Kim added:
“This award goes beyond a technical endorsement — it proves that Supercent’s AI strategy is delivering real business results. We will keep building an environment where AI takes care of repetitive work, so our teams can focus on creative and truly essential challenges.”

He also emphasized the significance of receiving the award in Vietnam:
“It is especially meaningful to share this news here in Vietnam. Supercent’s expansion into Vietnam is not about simple cost reduction; it is an investment in the country’s cultural diversity and the global potential of its young talent. By bringing Supercent’s AI-driven DNA to the local market and growing AI talent together, we aim to create a virtuous cycle of growth for both countries.”

Since relocating its headquarters in August, Supercent has been accelerating large-scale hiring and organizational expansion. Guided by the principle that “AI is not a technology that replaces people, but a tool that amplifies performance and creativity,” the company plans to further strengthen its AI teams and infrastructure. Supercent aims to embed AI across the entire value chain — from publishing systems to game development and live operations — and to build repeatable, scalable success stories in the global mobile gaming market.

Official Social Media
Company Website: https://en.supercent.io
YouTube: https://www.youtube.com/@supercent_official
Instagram: https://www.instagram.com/supercent_official
TikTok: https://www.tiktok.com/@supercent.official

Sunaofe Launches the All-in-One Standing Desk: Lunar Desk Offers Innovative Solutions for Modern Workspaces, Now Live on Kickstarter

By
Advertorial Desk
-

SINGAPORE, Nov. 17, 2025 /PRNewswire/ — Sunaofe, backed by global workspace leader SUNON (serving 160+ Fortune 500 companies), is excited to introduce the Lunar Standing Desk, an All-in-One ergonomic sit-and-stand desk designed to transform modern home offices and professional environments. Drawing from extensive user feedback and competitor insights, Sunaofe has addressed key pain points like complex assembly, limited height ranges, and cluttered setups—delivering superior stability, smart features, and sleek design at an unbeatable value.


Sunaofe Launches the All-in-One Standing Desk: Lunar Desk Offers Innovative Solutions for Modern Workspaces, Now Live on Kickstarter. The Lunar Desk is live on Kickstarter, already gaining strong early support with over 3,000 pre-launch sign-ups. Follow the project now to unlock the Super-Early-Bird pricing starting at $439 and join a community redefining the workspaces.

The Lunar Desk is live on Kickstarter, already gaining strong early support with over 3,000 pre-launch sign-ups. Follow the project now to unlock the Super-Early-Bird pricing starting at $439 and join a community redefining the workspaces.

Key Features:

  • Wool Felt Cable Management: Hidden trays and outlets keep wires neatly organized and desktops clutter-free.
  • Wide Height Adjustment: Smooth, silent operation from 28″ to 51.2″, with memory presets for 3 heights—ideal for users 5’2″ to 6’7″.
  • Unmatched Stability: Reinforced structure supports up to 350 lbs, even with heavy monitors or equipment.
  • Sleek, Rounded Design: Moon-inspired aesthetics with soft edges for safety and seamless fit in any decor.
  • Safety & Smarts: Anti-collision sensors, integrated wireless charging, drawers, hooks, and modular add-ons like storage bags and casters.
  • Easy Assembly: Features pre-embedded frames and minimal screws for quick setup.
  • Eco-Conscious Build: BIFMA-certified MDF desktop with 5-year warranty on core components.

Priced for accessibility yet built with premium engineering (including advanced German and Italian production lines), the Lunar Desk combines whisper-quiet dual motors, customizable sizes (48–72″ widths), and effortless organization to boost health, focus, and productivity. Recognized for excellence, Sunaofe and SUNON have earned prestigious accolades including the German Design Award, iF Design Award, and Good Design Award, underscoring our commitment to innovative, user-centered design trusted by industry leaders.

About Sunaofe

Powered by SUNON(S) PTE. LTD.—a 30-year industry expert with R&D in Berlin and service in 115 countries—Sunaofe prioritizes user-centered innovation. With 1,601+ patents, we craft sustainable, health-focused solutions that evolve with you.

Support the Lunar Desk on Kickstarter today and be among the first to experience the next evolution in standing desks. Early backers will receive exclusive discounts and limited-edition rewards as a thank-you for their support. Follow now for updates, exclusive perks, and to back the future of ergonomic workspaces: https://www.kickstarter.com/projects/sunaofe-desk/sunaofe-all-in-one-ergonomic-sit-and-stand-desk. Stay connected via sunaofe.com or our VIP Facebook Group (https://www.facebook.com/groups/sunaofesitandstanddesk/) for behind-the-scenes and giveaways.

Website: sunaofe.com 
YouTube: @sunaofe_furniture
Instagram: @sunaofe.official

2025 World Trade Centers Association Member Forum Advances Private Sector’s Role in Strengthening Global Business Ties

By
Advertorial Desk
-

WTCA members gathered to engage in cross-generational dialogue, trade-centered networking and global-first business growth

NEW YORK, Nov. 17, 2025 /PRNewswire/ —  World Trade Centers Association® (WTCA®), an international trade organization connecting more than 300 World Trade Center® (WTC®) locations in nearly 100 countries and territories, held its 2025 WTCA Member Forum from October 27-29. The three-day virtual event brought together 280 registrants, representing 105 WTC businesses across 43 countries and territories.

Under the theme “Empowering Emerging Voices,” this year’s event highlighted WTCA’s rising leaders and the experienced voices who guide, mentor and empower international trade collaboration. Sessions, panel discussions, and interactive workshops offered actionable tools for navigating a changing international landscape, reflecting WTCA’s commitment to promoting free and fair trade, open markets and healthy competition.

Highlights from this year’s Member Forum included a “Mentor-Mentee Match Up” session, where experienced leaders shared their insights and expertise with emerging voices within the network, as well as “The State of Global Trade and Investment” with Michael Blanga-Gubbay, Research Economist, World Trade Organization (WTO); “Networking with a Purpose” with Melinda Emerson, President, SmallBizLady Enterprises; “Digital Literacy for Trade Pros: Smart Tools, Big Impact” with Krishna Kumar, Co-Founder and CEO, GreenPepper AI; and “Cross-Cultural Communication in a Global Network” with Tamir Maharaj, Trade Advisor, WTC Winnipeg.  

“Our members’ dedication and collaboration in navigating rapidly shifting trade times has been remarkable. The energy and support that they offer one another demonstrate the strength and adaptability of our network. It is inspiring to see how WTCA continues to evolve and help members succeed in an ever-shifting global trade landscape,” said John E. Drew, WTCA Chair, Board of Directors. “At its core, WTCA’s mission is to empower WTC locations with the tools and connections they need to support the businesses they serve. By strengthening our members, we strengthen the businesses and communities navigating today’s complex geopolitical and trade realities, ultimately fulfilling our purpose of ‘Connecting Businesses, Globally,’ for shared growth and resilience.”

This year’s Forum also introduced the WTCA Visionary Awards, recognizing the groundbreaking projects of WTC businesses and their affiliated companies. This prestigious program highlights innovation, impact, and leadership within the WTCA network, providing businesses an opportunity to gain recognition and elevate their profile on a global stage. Through the Visionary Awards, WTC businesses and their affiliates can showcase their achievements and strengthen their presence within the international WTCA community.

“The 2025 Member Forum provided a valuable space for members to learn, share insights and discuss global trade trends,” said Crystal Edn, WTCA Executive Director-Member Services. “We have already heard that participants gained actionable takeaways from sessions on cross-cultural collaboration. We look forward to continuing these productive, transcontinental conversations at the 56th Annual WTCA Global Business Forum in Philadelphia.”

The 2025 WTCA Member Forum marked the official countdown to the highly anticipated 56th Annual WTCA Global Business Forum (GBF), which will be hosted April 19-22, 2026, in the United States by WTC Greater Philadelphia in Philadelphia, Pennsylvania.

“As we look toward the 2026 WTCA GBF, our focus is on honoring our shared traditions while advancing the innovation and collaboration that define the WTCA network today. Philadelphia is proud to host and invite our global partners to join us as we highlight the leadership, ideas and connections shaping the future of international business,” said Thomas Young, President and CEO of WTC Greater Philadelphia.

For more information about the 2026 WTCA Global Business Forum, please click here.

MEDIA CONTACTS:

World Trade Centers Association (WTCA)
Chanelle Dimalanta
Phone: +1 212 432 2644
Email: cdimalanta@wtca.org

Violet PR
Kate Traina
Phone: +1 908 967 2117
Email: kate@violetpr.com

About World Trade Centers Association (WTCA)
World Trade Centers Association (WTCA) is a network of more than 300 highly connected, mutually supporting businesses and organizations in nearly 100 countries and territories. As the owner of the “World Trade Center” and “WTC” trademarks, WTCA licenses exclusive rights to these brands for members to use in conjunction with their independently owned, iconic properties, facilities and trade services offerings. Through a robust portfolio of events, programming and resources that it offers its members, the goal of WTCA is to help local economies thrive by encouraging and facilitating trade and investment across the globe, creating an ecosystem built around commerce, community and connection. To learn more, visit www.wtca.org.

MiTAC Computing Unveils Advanced AI Cluster and Cooling Solutions at Supercomputing 2025

By
Advertorial Desk
-

ST. LOUIS, Nov. 17, 2025 /PRNewswire/ — MiTAC Computing Technology, a global leader in high-performance and energy-efficient server solutions, is proud to announce its participation at the Supercomputing (SC) 2025 (November 18–20, St. Louis, Missouri), booth 3916. Under the theme “AI Cluster Power – Cool Fast Scale Faster” MiTAC will showcase its modular highly scalable rack infrastructure for demanding AI and HPC workloads demonstrating capabilities from single servers to cluster integration focusing on liquid cooling and energy-efficient designs. MiTAC collaborates with AMD, Broadcom, CoolIT, Intel, KIOXIA, Micron, NVIDIA, Samsung and Solidigm to accelerate advanced computing and high-efficiency data centers.

AI Cluster Power. Cool Fast. Scale Faster.
AI Cluster Power. Cool Fast. Scale Faster.

Rack-scale Innovation From Standard Architecture to AI Cluster Excellence

At SC 2025 MiTAC Computing presents its full range of rack-level solutions for cluster-scale deployments including liquid-cooled and air-cooled AI and HPC racks addressing both open architectures and traditional enterprise data centers.

AI Liquid-Cooled Rack with AMD Instinct™ MI355X GPUs | Optimized for Ultra-Scale AI

The high-density 48U EIA AI liquid-cooled rack MR1100 series targets hyperscale AI training and inference. This robust solution supports 64 to 256 AI GPUs. Utilizing cold-plate technology with the latest AMD Instinct™ MI355X GPUs, AMD EPYC™ 9005 CPUs, and AMD Pensando™ Pollara 400 AI NICs, it ensures non-throttled AI throughput with 400/800 Gb/s network architecture.

AI Air-Cooled Rack with AMD Instinct™ MI350X GPUs | Standardized Architecture with High-Speed Interconnect

MiTAC presents its standard EIA 45U air-cooled AI rack, MR1100A, with four MiTAC G8825Z5 systems using AMD Instinct™ MI350X/MI325X GPUs. The 800Gb/s network switch Broadcom Tomahawk 5 chipset ensures low-latency data transmission GC68C-B8056 management and TS70A-B8056 storage servers enable rapid deployment of scalable AI/HPC clusters.

OCP ORv3 Liquid-Cooled Rack | Modular Power and Advanced Thermal Management

MiTAC’s 43OU OCP ORv3 liquid-cooled rack, MR is designed for sustainable HPC, accommodating up to 14 C2811Z5 multi-node servers powered by AMD EPYC™ 9005 Series processors. It integrates MiTAC Lake Erie storage, a 33kW Power Shelf, and the CoolIT 200kW CHx200+ In-Rack CDU. This modular design ensures stable, energy-efficient operation for high-density compute servers.

AI Acceleration Platforms

HPC & Cloud Computing Frameworks

  • G4520G6: This highly adaptable server, powered by the latest Intel® Xeon® 6 CPUs, delivers superior performance per watt for cloud and HPC roles, leveraging Micron DDR5 DRAM. It also features extensive expansion options, including support for NVIDIA RTX PROTM 6000 Blackwell Server Edition and NVIDIA Hopper GPUs.
  • C2811Z5: An OCP-compliant liquid-cooled multi-node server, it uses AMD EPYC™ 9005 series processors. Optimized with NVMe E1.S interfaces and Micron 9550 NVMe SSDs, it guarantees sustained high-speed data delivery for intensive HPC.

Enterprise Data Solutions

  • M2810Z5: Optimized for peak storage performance by deploying Kioxia XD8 E1.S Gen5 SSDs, this server unlocks maximum bandwidth for IO-intensive database applications.
  • R2520G6: A high-capacity 2U server with dual Intel® Xeon® 6700P series processors integrates Solidigm D7-PS1010 SSDs. PCIe 5.0 bandwidth guarantees stability for data warehousing and analytics.
  • M2510G6: This high-reliability platform supports Samsung MZTL67T6HBLC-00AW7 SSDs for mission-critical enterprise settings and demanding data processing.
  • R2513G6: This platform provides maximum archival capacity using Seagate EXOS M 30TB HDDs, tailored for organizations with immense data retention needs.

Global Success Stories Demonstrating MiTAC’s Value in AI & HPC Deployments Worldwide

At SC 2025, MiTAC showcases real-world success cases highlighting its proven expertise in delivering comprehensive rack-level solutions and its commitment to cluster-scale integration.

  • MiTAC and French CSP pioneer sustainable HPC achieving world-class PUE and operational cost reduction: Partnered with Qarnot using the Capri 3 OCP server to capture 95% of server heat for reuse, achieving a PUE of 1.01 and reducing operational costs by 50% for clients in Europe. The exhibit also highlights the integration of the Broadcom N1400GD network adapter.
  • OCP deployment accelerated in the US data centers featuring ORv3 platform and resource efficiency: MiTAC partnered with CTCA, a global IT solutions provider, to accelerate OCP deployment across the US data centers. This success leveraged the ORv3-compliant OCP server and advanced rack integration. The SC showcase highlights the OCP server featuring Samsung M321R8GA0EB2-CCP Memory, emphasizing faster rollouts and resource efficiency.
  • Rack integration streamlines global operations for leading cloud security provider: MiTAC provided customized, ready-to-deploy rack integration services, utilizing the GC68C-B8056 server. This service streamlined operations by delivering over 380 configurations across 150 data centers worldwide, meeting 48-hour turnaround times, and enabling a GPU-first infrastructure shift within half a year, demonstrating the consistency, agility, and innovation MiTAC provides.
  • MiTAC and its software-defined storage partner maximize GPU performance by eliminating AI training bottlenecks: Collaborating with a leading software-defined storage (SDS) partner, MiTAC leveraged the GC68A-B8056 server to remove critical I/O constraints. The pre-validated architecture boosted GPU utilization by 35% and delivered over 200 GB/s throughput, effectively tripling the speed of AI training completion.

For more SC information and product catalogs please visit:

About MiTAC Computing Technology Corporation

MiTAC Computing Technology Corp., a subsidiary of MiTAC Holdings, delivers comprehensive, energy-efficient server solutions backed by industry expertise dating back to the 1990s. Specializing in AI, HPC, cloud, and edge computing, MiTAC Computing employs rigorous methodologies to ensure uncompromising quality—across barebones, systems, racks, and cluster levels—fully achieving performance and integration. This commitment to quality at every level sets MiTAC Computing apart in the industry.

With a worldwide presence and end-to-end capabilities—from R&D and manufacturing to global support—MiTAC Computing provides agile, customized platforms for hyperscale data centers, HPC, and AI applications, ensuring optimal performance and scalability to meet unique business needs. By leveraging the latest advancements in AI and liquid cooling, and unifying the MiTAC brand with Intel DSG and TYAN server products, MiTAC Computing stands out for its innovative, efficient, and reliable server technology as well as its hardware and software integrated solutions—empowering businesses to meet future challenges.

MiTAC Computing Technology Corporation website: https://www.mitaccomputing.com/

1...1,7031,7041,705...6,383Page 1,704 of 6,383